JP2001527052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001527052A5 JP2001527052A5 JP2000526243A JP2000526243A JP2001527052A5 JP 2001527052 A5 JP2001527052 A5 JP 2001527052A5 JP 2000526243 A JP2000526243 A JP 2000526243A JP 2000526243 A JP2000526243 A JP 2000526243A JP 2001527052 A5 JP2001527052 A5 JP 2001527052A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- lipid
- composition
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 41
- 239000000203 mixture Substances 0.000 description 38
- 150000002632 lipids Chemical class 0.000 description 32
- 229910052739 hydrogen Inorganic materials 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- 239000003446 ligand Substances 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 150000003904 phospholipids Chemical class 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 6
- 239000012867 bioactive agent Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- -1 mercapto, hydrazino Chemical group 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11365897P | 1997-12-23 | 1997-12-23 | |
| US7385298P | 1998-02-02 | 1998-02-02 | |
| US60/073,852 | 1998-02-02 | ||
| US60/113,658 | 1998-02-02 | ||
| PCT/CA1998/001185 WO1999033493A1 (en) | 1997-12-23 | 1998-12-22 | Polyamide oligomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001527052A JP2001527052A (ja) | 2001-12-25 |
| JP2001527052A5 true JP2001527052A5 (https=) | 2006-02-23 |
Family
ID=26754961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000526243A Pending JP2001527052A (ja) | 1997-12-23 | 1998-12-22 | ポリアミドオリゴマー |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1041976B1 (https=) |
| JP (1) | JP2001527052A (https=) |
| AT (1) | ATE322255T1 (https=) |
| AU (1) | AU751434B2 (https=) |
| CA (1) | CA2315695A1 (https=) |
| DE (1) | DE69834133D1 (https=) |
| WO (1) | WO1999033493A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| ATE443528T1 (de) | 1998-01-05 | 2009-10-15 | Univ Washington | Erhöhter transport unter benutzung membranzerstörender stoffe |
| WO2003000291A1 (fr) * | 2001-06-22 | 2003-01-03 | Techno Network Shikoku Co., Ltd. | Vesicules lipidiques, processus de production de vesicules lipidiques et procede d'immobilisation de gene sur ces vesicules lipidiques |
| CA2474138A1 (en) * | 2002-01-15 | 2003-07-24 | Vanderbilt University | Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system |
| DK1499294T3 (da) * | 2002-04-29 | 2010-12-06 | Biotesys Gmbh | Polymeriserede, peptid-modificerede lipider som biologiske transportsystemer til mikronæringsstoffer |
| WO2003097805A2 (en) | 2002-05-15 | 2003-11-27 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| EP1578954A4 (en) | 2002-12-11 | 2010-08-11 | Coley Pharm Group Inc | 5'-CPG NUCLEIC ACIDS AND USE METHOD |
| US7332164B2 (en) * | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| US20090232731A1 (en) * | 2006-05-18 | 2009-09-17 | Martin Funk | Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis |
| EP2788006B1 (en) | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| EP3668834B1 (en) | 2017-08-17 | 2024-10-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| JP7543259B2 (ja) | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| MY202837A (en) | 2019-01-11 | 2024-05-24 | Acuitas Therapeutics Inc | Lipids for lipid nanoparticle delivery of active agents |
| WO2022016070A1 (en) | 2020-07-16 | 2022-01-20 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| CN113636931B (zh) * | 2021-08-05 | 2024-02-13 | 康龙化成(宁波)科技发展有限公司 | 基因编码化合物库起始头片段化合物及其在基因编码化合物库合成上的应用 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4426330A (en) * | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US5135737A (en) * | 1986-11-10 | 1992-08-04 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Amplifier molecules for enhancement of diagnosis and therapy |
| JPH0720857B2 (ja) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| DE4004296A1 (de) * | 1990-02-13 | 1991-08-14 | Hoechst Ag | Verbesserte markierte haptene, verfahren zu deren herstellung sowie verwendung dieser markierten haptene in immunoassays |
| JP3351476B2 (ja) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
-
1998
- 1998-12-22 CA CA002315695A patent/CA2315695A1/en not_active Abandoned
- 1998-12-22 AT AT98962158T patent/ATE322255T1/de not_active IP Right Cessation
- 1998-12-22 DE DE69834133T patent/DE69834133D1/de not_active Expired - Lifetime
- 1998-12-22 JP JP2000526243A patent/JP2001527052A/ja active Pending
- 1998-12-22 WO PCT/CA1998/001185 patent/WO1999033493A1/en not_active Ceased
- 1998-12-22 EP EP98962158A patent/EP1041976B1/en not_active Expired - Lifetime
- 1998-12-22 AU AU17460/99A patent/AU751434B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001527052A5 (https=) | ||
| US9717685B2 (en) | Lipid-coated nucleic acid nanostructures of defined shape | |
| US6858226B2 (en) | Fusogenic lipids and vesicles | |
| CN102824647B (zh) | 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法 | |
| CN100384480C (zh) | 核酸传递系统 | |
| US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
| JP4951338B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| US6943027B2 (en) | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery | |
| JP3907662B2 (ja) | 自己構築ポリヌクレオチド送達システム | |
| JP2008518998A (ja) | 活性物質としてオリゴヌクレオチドを含む医薬組成物におけるまたはそれに関する改善 | |
| JPH11512712A (ja) | 生物学的に活性な物質を細胞に送達するためのエマルジョンおよびミセル処方物 | |
| JP2011503070A (ja) | 全身遺伝子送達のための自己構築型ミセル様ナノ粒子 | |
| JP2001502299A (ja) | リポソーム | |
| US5739271A (en) | Thiocationic lipids | |
| JP2008525514A (ja) | コーティングされた脂質複合体およびそれらの使用 | |
| JP2002501511A (ja) | 脂質小胞への荷電した治療剤の高率封入 | |
| JP2007512355A (ja) | 開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達 | |
| CN116615233A (zh) | 用于使生物分子在受试者中表达的系统和方法 | |
| CA3262393A1 (en) | Lipid composition targeting antigen-presenting cells, and related uses | |
| JP2005515990A (ja) | 化合物 | |
| US20040077888A1 (en) | Polyamine-mediated transfection | |
| CA2222586A1 (en) | Thiocationic lipids, pharmaceutical compositions and methods of use thereof | |
| US5759519A (en) | Method for the intracellular delivery of biomolecules using thiocationic lipids | |
| US8883989B2 (en) | Fractalkine binding polynucleotides and methods of use | |
| US5756352A (en) | Thiocationic lipid-nucleic acid conjugates |